Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Affiliations

• ¹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
• ² Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
• ³ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA.
• ⁴ Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
• ⁵ Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
• ⁶ Department of Pathology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
• ⁷ Medical College of Georgia Cancer Center, Augusta, Georgia, USA.
• ⁸ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. chiosisg@mskcc.org.
• ⁹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.
• ¹⁰ Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.